Bio-Bridge Science (BGES.OB) Featured in Wall Street Reporter

Bio-Bridge-Science Inc. (BGES.OB) announced that CEO Dr.
Liang Qiao is featured in an interview with the Wall Street Reporter
Senior Analyst Ian Roberts. The topics of discussion include the
company's unique technology platform and its promising new HIV
vaccine.
   Dr. Qiao also elaborates upon Bio-Bridge Science's plans and
prospects for the upcoming year.
   The interview is available now on www.wallstreetreporter.com and
can be accessed through the 'Interviews A thru Z link' under
Bio-Bridge Science.

   About Bio-Bridge Science:

   Bio-Bridge Science is a biotechnology firm focused on the
development of vaccines with broad therapeutic and preventive
applications. Through its wholly owned subsidiary in Beijing,
Bio-Bridge is developing a promising new HIV Vaccine, that is expected
to enter clinical trials early next year in China. The vaccine, based
on exclusive technology co-developed by CEO Liang Qiao, an associate
professor at Loyola University Chicago's Strich School of Medicine,
targets infection in mucosal tissues, the first type of tissue
attacked by HIV.
   The Chinese government, mindful of the rapid expansion of AIDS in
China has, through the "Green Mile Policy" acted to expedite the
approval of domestically produced HIV Vaccines and has dramatically
increased its spending on AIDS-related research. In accordance with
this policy, Bio-Bridge expects to bring its therapeutic HIV Vaccine
to market as early as 2008, far in advance of many other HIV Vaccines
currently in development. Bio-Bridge is currently constructing a new
$3 million state-of-the-art GMP research and manufacturing facility in
Beijing, which is expected to be completed by the end of this year.